Howbert, J. Jeffry,Duvvuri, Muralikrishna,Hershberg, Rob,Dietsch, Greg
申请号：
AU2016203386
公开号：
AU2016203386B2
申请日:
2016.05.24
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
#$%^&*AU2016203386B220170706.pdf#####ABSTRACT The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
